Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study
Objective: To assess the efficacy and safety of ribavirin and interferon-α (RBV/IFN-α) therapy in COVID-19 patients. Methods: A multicenter, retrospective cohort study of COVID-19 patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31 March 2020. Patients were divided...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-03-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221000667 |
| _version_ | 1818622357512650752 |
|---|---|
| author | Hui Li Nian Xiong Changjun Li Yanhong Gong Li Liu Heping Yang Xiangping Tan Nan Jiang Qiao Zong Jing Wang Zuxun Lu Xiaoxv Yin |
| author_facet | Hui Li Nian Xiong Changjun Li Yanhong Gong Li Liu Heping Yang Xiangping Tan Nan Jiang Qiao Zong Jing Wang Zuxun Lu Xiaoxv Yin |
| author_sort | Hui Li |
| collection | DOAJ |
| description | Objective: To assess the efficacy and safety of ribavirin and interferon-α (RBV/IFN-α) therapy in COVID-19 patients. Methods: A multicenter, retrospective cohort study of COVID-19 patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31 March 2020. Patients were divided into 2 groups according to their exposure to RBV/IFN-α therapy within 48 h of admission. Mixed-effect Cox model and Logistic regression were used to explore the association between early treatments of RBV/IFN-α and primary outcomes. Results: Of 2037 patients included, 1281 received RBV/IFN-α (RBV, IFN-α or RBV combined with IFN-α) treatments and 756 received none of these treatments. In a mixed effect model, RBV/IFN-α therapy was not associated with progression from non-severe into severe type (adjusted hazard ratio (aHR) = 1.09, 95% CI: 0.88−1.36) or with reduction in 30-day mortality (aHR = 0.89, 95% CI: 0.61−1.30). However, it was associated with a higher probability of hospital stay >15 days (adjusted odds ratio (aOR) = 2.11, 95% CI: 1.68−2.64) compared with no RBV/IFN-α therapy. The propensity score-matched cohort and subgroup analysis displayed similar results. Conclusion: RBV/IFN-α therapy was not observed to improve clinical outcomes in COVID-19 patients suggesting that RBV/IFN-α therapy should be avoided in COVID-19 treatment. |
| first_indexed | 2024-12-16T18:23:53Z |
| format | Article |
| id | doaj.art-082d5e9f4e074697848bebf737153d26 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-16T18:23:53Z |
| publishDate | 2021-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-082d5e9f4e074697848bebf737153d262022-12-21T22:21:28ZengElsevierInternational Journal of Infectious Diseases1201-97122021-03-01104641648Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort studyHui Li0Nian Xiong1Changjun Li2Yanhong Gong3Li Liu4Heping Yang5Xiangping Tan6Nan Jiang7Qiao Zong8Jing Wang9Zuxun Lu10Xiaoxv Yin11Department of Social Medicine and Health Management, School of Public Health, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Neurology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Social Medicine and Health Management, School of Public Health, Huazhong University of Science and Technology, Wuhan, ChinaOffice of Academic Research, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaSchool of Nursing, Wuchang University of Technology, Wuhan, ChinaLichuan Center for Disease Control and Prevention, Enshi Tujia and Miao Autonomous Prefecture, ChinaDepartment of Social Medicine and Health Management, School of Public Health, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Social Medicine and Health Management, School of Public Health, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Social Medicine and Health Management, School of Public Health, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Social Medicine and Health Management, School of Public Health, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Social Medicine and Health Management, School of Public Health, Huazhong University of Science and Technology, Wuhan, China; Corresponding author at: Department of Social Medicine and Health Management, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hangkong Road, Wuhan 430030, China.Objective: To assess the efficacy and safety of ribavirin and interferon-α (RBV/IFN-α) therapy in COVID-19 patients. Methods: A multicenter, retrospective cohort study of COVID-19 patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31 March 2020. Patients were divided into 2 groups according to their exposure to RBV/IFN-α therapy within 48 h of admission. Mixed-effect Cox model and Logistic regression were used to explore the association between early treatments of RBV/IFN-α and primary outcomes. Results: Of 2037 patients included, 1281 received RBV/IFN-α (RBV, IFN-α or RBV combined with IFN-α) treatments and 756 received none of these treatments. In a mixed effect model, RBV/IFN-α therapy was not associated with progression from non-severe into severe type (adjusted hazard ratio (aHR) = 1.09, 95% CI: 0.88−1.36) or with reduction in 30-day mortality (aHR = 0.89, 95% CI: 0.61−1.30). However, it was associated with a higher probability of hospital stay >15 days (adjusted odds ratio (aOR) = 2.11, 95% CI: 1.68−2.64) compared with no RBV/IFN-α therapy. The propensity score-matched cohort and subgroup analysis displayed similar results. Conclusion: RBV/IFN-α therapy was not observed to improve clinical outcomes in COVID-19 patients suggesting that RBV/IFN-α therapy should be avoided in COVID-19 treatment.http://www.sciencedirect.com/science/article/pii/S1201971221000667COVID-19Antiviral therapyRibavirinInterferon-αCohort studies |
| spellingShingle | Hui Li Nian Xiong Changjun Li Yanhong Gong Li Liu Heping Yang Xiangping Tan Nan Jiang Qiao Zong Jing Wang Zuxun Lu Xiaoxv Yin Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study International Journal of Infectious Diseases COVID-19 Antiviral therapy Ribavirin Interferon-α Cohort studies |
| title | Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study |
| title_full | Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study |
| title_fullStr | Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study |
| title_full_unstemmed | Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study |
| title_short | Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study |
| title_sort | efficacy of ribavirin and interferon α therapy for hospitalized patients with covid 19 a multicenter retrospective cohort study |
| topic | COVID-19 Antiviral therapy Ribavirin Interferon-α Cohort studies |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221000667 |
| work_keys_str_mv | AT huili efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT nianxiong efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT changjunli efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT yanhonggong efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT liliu efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT hepingyang efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT xiangpingtan efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT nanjiang efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT qiaozong efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT jingwang efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT zuxunlu efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy AT xiaoxvyin efficacyofribavirinandinterferonatherapyforhospitalizedpatientswithcovid19amulticenterretrospectivecohortstudy |